© 2020 MJH Life Sciences™ and Neurology Live. All rights reserved.
Top Medical News
NeurologyLive Friday 5 — September 18, 2020
September 18, 2020
By NeurologyLive Staff
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 18, 2020.
The Metamorphosis of Migraine: Evidence and Epidemiology
September 18, 2020
By Matt Hoffman
The ongoing fight to add to the epidemiologic understanding of migraine is explored in part 2 of this special 3-part multimedia series on the evolution of migraine care.
Ozanimod Shows Long-Term Safety, Efficacy in Open-Label Extension
September 18, 2020
By Marco Meglio
Along with being generally well tolerated, ozanimod was able to help most patients become relapse free without disability progression.
Sumifilam Improves Multiple Alzheimer Disease Biomarkers in Phase 2b Study
September 17, 2020
By Marco Meglio
The results point to the potential for sumifilam to become a transformative treatment for patients with Alzheimer disease.
Addressing Loneliness and Social Isolation in Patients With Parkinson Disease
September 17, 2020
By Matt Hoffman
The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers offered background the inspiration for the study and why loneliness should be addressed in these patients.
Featured
Latest Videos
Most Recent
Satralizumab Reduces Risk of Relapse, Including in Treatment-Naïve NMOSD
September 17, 2020
Article
Two posters presented at MS 2020 confirm satralizumab’s ability to reduce protocol-defined relapse including in patients with treatment-naïve NMOSD.
Apomorphine Sublingual Film Shows Long-Term Efficacy in OFF Episode Treatment
September 16, 2020
Article
The recently approved apomorphine sublingual film (Kynmobi; Sunovion) maintained efficacy over the long-term, with at least 74% of patients experiencing full ON within 30 minutes post-dose at each time point.
THN102 Is Safe, Improves Excessive Daytime Sleepiness in Parkinson Disease
September 16, 2020
Article
The investigational drug consistently increased the proportion of patients no longer suffering from daytime sleepiness during treatment.
Jakob Dupont, MD: Phase 1 Data on Cell Therapy for Progressive MS
September 16, 2020
Video
The executive vice president and head of global research and development at Atara Biotherapeutics spoke to the findings of a phase 1 study of the cell therapy ATA188.
Neurology Residency Training During a Pandemic
September 16, 2020
Article
In part 2 of this interview, Leah Croll, MD, a neurology resident on the front lines of the COVID-19 pandemic, describes how her resident program experience was impacted by the pandemic.
Amantadine Shows Treatment Durability for Reducing OFF Time in Parkinson Disease
September 15, 2020
Article
The percentage of patients reporting no OFF time and no impact of OFF on daily function more than doubled by the first on-treatment visit in this open-label trial.
Tau Levels May Predict Early Disability, Worse Prognosis in MS
September 15, 2020
Article
Data show that higher CSF tau levels at diagnosis correlated with worse disability independent of age, though no such associations were identified with amyloid-beta.
Levodopa-Carbidopa Intestinal Gel Superior to Immediate Release Capsules for ON Time Without Dyskinesia
September 15, 2020
Article
Benefits of levodopa-carbidopa intestinal gel lasted throughout the day and showed greater benefits of continuous dopaminergic stimulation in disease control than immediate release oral capsules.
Opicapone Improves ON, OFF Time in Levodopa-Treated Patients With Parkinson Disease
September 14, 2020
Article
The COMT inhibitor, which was approved in April 2020, may be a worthwhile option as a first-line adjunctive treatment for those with Parkinson disease with motor fluctuations.
Levodopa-Carbidopa Intestinal Gel Effective for Dyskinesia in Advanced Parkinson Disease
September 14, 2020
Article
Improvement in dyskinesia occurred after 2 weeks of treatment with levodopa-carbidopa intestinal gel and was sustained throughout the study.